Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 774 posts found.

simon_lowth_az

Simon Lowth exits AstraZeneca

July 15, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, simon lowth

AstraZeneca’s chief financial officer and executive director Simon Lowth will leave the firm at the end of October. Lowth has …

Appointment
AZ Cambridge

AstraZeneca shores up Cambridge move

July 11, 2013
Research and Development, Sales and Marketing AstraZeneca, Cambridge, research and development

AstraZeneca has cemented its position in Cambridge, the UK location of its purpose-built global HQ from 2016, by signing deals …

News
Cambridge image

AstraZeneca chooses Cambridge for global HQ

June 19, 2013
Research and Development, Sales and Marketing AstraZeneca, Cambridge, MedImmune

AstraZeneca has chosen the Cambridge Biomedical Campus on the outskirts of the city as a new research and corporate hub. …

News
Medimmune image

MedImmune signs diabetes deal

June 18, 2013
Research and Development, Sales and Marketing AstraZeneca, MedImmune, diabetes

AstraZeneca R&D subsidiary MedImmune has signed a deal with privately-owned San Francisco-based NGM Biopharmaceuticals to discover novel therapeutics to treat …

News
astrazeneca image

AstraZeneca to pay up to $1.2 billion for Pearl

June 10, 2013
Research and Development, Sales and Marketing AstraZeneca, COPD, pearl therapeutics

AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …

News
astrazeneca image

AstraZeneca abandons late-stage RA drug

June 5, 2013
Research and Development, Sales and Marketing AstraZeneca, RA, Rigel

AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …

News
astrazeneca image

AstraZeneca/BMS drug granted speedy FDA review

June 5, 2013
Sales and Marketing AstraZeneca, BMS, lipodystrophy

AstraZeneca and partner Bristol-Myers Squibb have been granted a priority review for their rare disease drug metreleptin. The medicine is …

News
AstraZeneca image

AstraZeneca and CRUK partner on drug trial

May 31, 2013
Sales and Marketing AstraZeneca, CRUK

AstraZeneca is partnering with Cancer Research UK to develop a new oncology medicine that targets a number of different cancers. …

News
astrazeneca image

AstraZeneca reveals Alderley Park plan

May 8, 2013
Research and Development, Sales and Marketing AstraZeneca, BioCity, R&D, alderley

AstraZeneca has left a key question about what to do with its soon-to-be defunct R&D site in Cheshire in the …

News
astrazeneca image

AstraZeneca signs $200m nanomedicine deal

April 23, 2013
Research and Development, Sales and Marketing AstraZeneca, bind therapeutics, nanomedicine

AstraZeneca has signed an agreement to develop and commercialise a cancer nanomedicine from US firm Bind Therapeutics’ stable of Accurins. …

News

Oxford Cancer Biomarkers signs discovery deal with AstraZeneca

April 18, 2013
Research and Development AstraZeneca, Oxford Cancer Biomarkers

AstraZeneca has signed a new alliance with a UK firm in the field of biomarker discovery.Oxford Cancer Biomarkers is developing …

News

MedImmune buys AlphaCore

April 9, 2013
Research and Development AlphaCore, AstraZeneca, MedImmune

AstraZeneca’s biologics R&D arm MedImmune has bought private US biotech firm AlphaCore Pharma for an undisclosed sum.The acquisition is part …

News
crestor image

AstraZeneca settles Crestor case

March 26, 2013
Sales and Marketing AstraZeneca, Crestor, Watson

AstraZeneca has settled a long-running legal battle over one of its biggest brands, Crestor, whose patent expires in 2016. The …

News

AstraZeneca hires strategy boss

March 25, 2013
Sales and Marketing AstraZeneca, dunoyer

AstraZeneca has poached one of GlaxoSmithKline’s senior executives to help push through its new growth strategy. Marc Dunoyer, global head …

News
Astrazeneca image

AstraZeneca sets out growth strategy

March 21, 2013
Sales and Marketing AstraZeneca, R&D

AstraZeneca has set out an ambitious plan designed to return it to growth which eschews diversification and sets great store …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024